325 related articles for article (PubMed ID: 38349409)
21. Alterations in the lipid profile associate with a dysregulated inflammatory, prothrombotic, anti-fibrinolytic state and development of severe acute kidney injury in coronavirus disease 2019 (COVID-19): A study from Cincinnati, USA.
Henry BM; Szergyuk I; de Oliveira MHS; Abosamak MF; Benoit SW; Benoit JL; Lippi G
Diabetes Metab Syndr; 2021; 15(3):863-868. PubMed ID: 33878674
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
Bouck EG; Denorme F; Holle LA; Middelton EA; Blair AM; de Laat B; Schiffman JD; Yost CC; Rondina MT; Wolberg AS; Campbell RA
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):401-414. PubMed ID: 33196292
[TBL] [Abstract][Full Text] [Related]
23. Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Gando S; Wada T
Front Immunol; 2021; 12():649122. PubMed ID: 34177896
[TBL] [Abstract][Full Text] [Related]
24. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?
Xu K; Wei Y; Giunta S; Zhou M; Xia S
Exp Gerontol; 2021 Aug; 151():111423. PubMed ID: 34048906
[TBL] [Abstract][Full Text] [Related]
25. Lung Epithelial Cell Transcriptional Regulation as a Factor in COVID-19-associated Coagulopathies.
FitzGerald ES; Chen Y; Fitzgerald KA; Jamieson AM
Am J Respir Cell Mol Biol; 2021 Jun; 64(6):687-697. PubMed ID: 33740387
[TBL] [Abstract][Full Text] [Related]
26. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy.
Seth R; McKinnon TAJ; Zhang XF
Am J Physiol Heart Circ Physiol; 2022 Jan; 322(1):H87-H93. PubMed ID: 34890277
[TBL] [Abstract][Full Text] [Related]
27. Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19.
Moosavi M; Wooten M; Goodman A; Nahab FB; Duncan A; Maier C; Guarner J
Am J Clin Pathol; 2021 Mar; 155(4):498-505. PubMed ID: 33300981
[TBL] [Abstract][Full Text] [Related]
28. COVID-19-associated coagulopathy and disseminated intravascular coagulation.
Asakura H; Ogawa H
Int J Hematol; 2021 Jan; 113(1):45-57. PubMed ID: 33161508
[TBL] [Abstract][Full Text] [Related]
29. Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus.
Katneni UK; Alexaki A; Hunt RC; Schiller T; DiCuccio M; Buehler PW; Ibla JC; Kimchi-Sarfaty C
Thromb Haemost; 2020 Dec; 120(12):1668-1679. PubMed ID: 32838472
[TBL] [Abstract][Full Text] [Related]
30. Immunity and coagulation and fibrinolytic processes may reduce the risk of severe illness in pregnant women with coronavirus disease 2019.
Zhong Y; Cao Y; Zhong X; Peng Z; Jiang S; Tang T; Chen H; Li X; Xia Y; Cheng Y; Zhao X
Am J Obstet Gynecol; 2021 Apr; 224(4):393.e1-393.e25. PubMed ID: 33098813
[TBL] [Abstract][Full Text] [Related]
31. Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.
Gando S; Wada T
Shock; 2022 Jan; 57(1):1-6. PubMed ID: 34172612
[TBL] [Abstract][Full Text] [Related]
32. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.
Dobesh PP; Trujillo TC
Pharmacotherapy; 2020 Nov; 40(11):1130-1151. PubMed ID: 33006163
[TBL] [Abstract][Full Text] [Related]
33. Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines.
Abdel-Bakky MS; Amin E; Ewees MG; Mahmoud NI; Mohammed HA; Altowayan WM; Abdellatif AAH
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215822
[TBL] [Abstract][Full Text] [Related]
34. Neutrophil extracellular traps and thrombosis in COVID-19.
Zuo Y; Zuo M; Yalavarthi S; Gockman K; Madison JA; Shi H; Woodard W; Lezak SP; Lugogo NL; Knight JS; Kanthi Y
J Thromb Thrombolysis; 2021 Feb; 51(2):446-453. PubMed ID: 33151461
[TBL] [Abstract][Full Text] [Related]
35. Multisystem Assessment of the Imaging Manifestations of Coagulopathy in Hospitalized Patients With Coronavirus Disease (COVID-19).
O'Shea A; Parakh A; Hedgire S; Lee SI
AJR Am J Roentgenol; 2021 Apr; 216(4):1088-1098. PubMed ID: 32755217
[No Abstract] [Full Text] [Related]
36. Coagulation and wound repair during COVID-19.
Menachery VD; Gralinski LE
J Heart Lung Transplant; 2021 Oct; 40(10):1076-1081. PubMed ID: 34334300
[TBL] [Abstract][Full Text] [Related]
37. Coagulation Dysfunction.
Fei Y; Tang N; Liu H; Cao W
Arch Pathol Lab Med; 2020 Oct; 144(10):1223-1229. PubMed ID: 32551814
[TBL] [Abstract][Full Text] [Related]
38. Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?
Paar V; Wernly B; Zhou Z; Motloch LJ; Hoppe UC; Egle A; Lichtenauer M
J Thromb Thrombolysis; 2021 Jan; 51(1):226-231. PubMed ID: 32632558
[TBL] [Abstract][Full Text] [Related]
39. Derangement of the coagulation process using subclinical markers and viscoelastic measurements in critically ill patients with coronavirus disease 2019 pneumonia and non-coronavirus disease 2019 pneumonia.
Pavoni V; Gianesello L; Pazzi M; Horton A; Suardi LR
Blood Coagul Fibrinolysis; 2021 Mar; 32(2):80-86. PubMed ID: 33196505
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 and coagulation disorders in different organs.
Vinayagam S; Sattu K
Life Sci; 2020 Nov; 260():118431. PubMed ID: 32946915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
